blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2897588

EP2897588 - AN INHALABLE MEDICAMENT [Right-click to bookmark this link]
StatusOpposition rejected
Status updated on  11.03.2022
Database last updated on 18.11.2024
FormerThe patent has been granted
Status updated on  14.06.2019
FormerGrant of patent is intended
Status updated on  07.06.2019
FormerExamination is in progress
Status updated on  28.05.2019
FormerGrant of patent is intended
Status updated on  22.04.2019
FormerExamination is in progress
Status updated on  03.11.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Teva Branded Pharmaceutical Products R&D, Inc.
41 Moores Road
Frazer PA 19355 / US
[2016/27]
Former [2015/31]For all designated states
Teva Branded Pharmaceutical Products R & D, Inc.
425 Privet Rd
Horsham, PA 19044 / US
Inventor(s)01 / DALVI, Mukui
Golden Glades Building
74 NW 176 Street
Miami, FL 33169 / US
02 / WU, Libo
Golden Glades Building
74 NW 176 Street
Miami, FL 33169 / US
 [2015/31]
Representative(s)Elkington and Fife LLP
Prospect House
8 Pembroke Road
Sevenoaks, Kent TN13 1XR / GB
[2019/29]
Former [2015/31]Gillard, Richard Edward
Elkington and Fife LLP
Thavies Inn House
3-4 Holborn Circus
London EC1N 2HA / GB
Application number, filing date14809248.921.11.2014
[2019/29]
WO2014US66872
Priority number, dateUS201361907782P22.11.2013         Original published format: US 201361907782 P
[2015/31]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015077594
Date:28.05.2015
Language:EN
[2015/21]
Type: A1 Application with search report 
No.:EP2897588
Date:29.07.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 28.05.2015 takes the place of the publication of the European patent application.
[2015/31]
Type: B1 Patent specification 
No.:EP2897588
Date:17.07.2019
Language:EN
[2019/29]
Search report(s)International search report - published on:EP28.05.2015
ClassificationIPC:A61K9/00
[2015/31]
CPC:
A61K9/0078 (EP,KR,US); A61K9/008 (EP,KR,US); A61K31/439 (US);
A61K31/46 (KR); A61K47/02 (KR,US); A61K47/06 (KR);
A61K47/10 (KR,US); A61M11/00 (KR,US); A61M15/0021 (KR,US);
A61M15/009 (KR,US); A61P11/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/31]
Extension statesBA22.01.2015
ME22.01.2015
TitleGerman:INHALIERBARES MEDIKAMENT[2015/31]
English:AN INHALABLE MEDICAMENT[2015/31]
French:MÉDICAMENT INHALABLE[2015/31]
Entry into regional phase22.01.2015National basic fee paid 
22.01.2015Designation fee(s) paid 
22.01.2015Examination fee paid 
Examination procedure22.01.2015Examination requested  [2015/31]
30.11.2015Amendment by applicant (claims and/or description)
07.11.2017Despatch of a communication from the examining division (Time limit: M04)
23.01.2018Reply to a communication from the examining division
15.05.2018Despatch of a communication from the examining division (Time limit: M04)
11.06.2018Reply to a communication from the examining division
23.04.2019Communication of intention to grant the patent
22.05.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.05.2019Fee for grant paid
22.05.2019Fee for publishing/printing paid
06.06.2019Information about intention to grant a patent
06.06.2019Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  06.02.2020  27.02.2020  ADMISSIBLE
Chiesi Farmaceutici S.p.A.
Via Palermo, 26/A
43122 Parma / IT
Opponent's representative
Bianchetti & Minoja with Trevisan & Cuonzo IPS SRL
Via Plinio, 63
20129 Milano / IT
 [N/P]
Former [2021/17]
Opponent(s)01  06.02.2020  27.02.2020  ADMISSIBLE
Chiesi Farmaceutici S.p.A.
Via Palermo, 26/A
43122 Parma / IT
Opponent's representative
Bianchetti Bracco Minoja S.r.l.
Via Plinio, 63
20129 Milano / IT
Former [2020/12]
Opponent(s)01  06.02.2020    ADMISSIBLE
CHIESI FARMACEUTICI S.p.A.
Via Palermo, 26/A
43122 Parma / IT
Opponent's representative
Bianchetti Bracco Minoja S.r.l.
Via Plinio, 63
20129 Milano / IT
18.06.2020Invitation to proprietor to file observations on the notice of opposition
26.10.2020Reply of patent proprietor to notice(s) of opposition
22.09.2021Date of oral proceedings
25.10.2021Despatch of minutes of oral proceedings
25.10.2021Date of despatch of rejection of opposition
02.03.2022Legal effect of rejection of opposition [2022/15]
Appeal following opposition23.12.2021Appeal received No.  T0013/22
23.12.2021Payment of appeal fee
02.03.2022Result of appeal procedure: appeal of the opponent withdrawn
Fees paidRenewal fee
23.11.2016Renewal fee patent year 03
24.11.2017Renewal fee patent year 04
22.11.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL17.07.2019
CY17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
MK17.07.2019
MT17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU21.11.2019
[2022/31]
Former [2021/34]AL17.07.2019
CY17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
MT17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU21.11.2019
Former [2021/26]AL17.07.2019
CY17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU21.11.2019
Former [2020/37]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
RO17.07.2019
RS17.07.2019
SI17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU21.11.2019
Former [2020/36]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
MC17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
LU21.11.2019
Former [2020/35]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
PT18.11.2019
LU21.11.2019
IS24.02.2020
Former [2020/27]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RO17.07.2019
RS17.07.2019
SK17.07.2019
SM17.07.2019
BG17.10.2019
GR18.10.2019
PT18.11.2019
IS24.02.2020
Former [2020/24]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RO17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
PT18.11.2019
IS24.02.2020
Former [2020/23]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RO17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/22]AL17.07.2019
EE17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/15]AL17.07.2019
HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/12]HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
IS17.11.2019
PT18.11.2019
Former [2020/11]HR17.07.2019
LT17.07.2019
LV17.07.2019
RS17.07.2019
BG17.10.2019
GR18.10.2019
PT18.11.2019
Former [2020/10]LT17.07.2019
BG17.10.2019
PT18.11.2019
Former [2020/08]LT17.07.2019
Cited inInternational search[A]US5676930  (JAGER PAUL DONALD [US], et al) [A] 1-15 * column 2, line 21 - line 51 * * column 3, line 37 - column 4, line 29 ** column 5, line 9 - line 48 *;
 [X]US2003149007  (CHAUDRY IMTIAZ [US], et al) [X] 1-5,11,14 * page 1, paragraph 0009 * * page 2, paragraph 0029 * * page 4, paragraph 0041 * * page 7, paragraph 0076 *;
 [I]EP2606891  (TEVA BRANDED PHARMACEUTICAL PRODUCTS INC [US]) [I] 1-15 * page 3, paragraphs 0011,0012,0018 * * claim 10 *
by applicantWO9209323
 GB2264238
 WO0193933
    - Drug Delivery to the Respiratory Tract, VCH PUBLISHERS, (1987), pages 87 - 88
    - Pharmaceutics - The Science of Dosage Form Design, CHURCHILL LIVINGSTONE, (2002), page 476
OppositionEP2606891
    - Anonymus, "The Merck Index. Point 1699", (19960101), page 272, XP055684266
    - Anonymus, "Manganese", Air Quality Guidelines -second Ed., (20010101), XP055684270
    - "Emergency Response Guidebook", PHMSA, (20120530), pages 1 - 392
    - Anonymus, "DOT Releases New Emergency Response Guidebook", PHMSA 13-12, (20120530), XP055684276
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.